ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
ProMIS Neurosciences reported positive blinded interim data from the Phase 1b PRECISE-AD trial of PMN310 for Alzheimer’s disease, showing no cases of ARIA-E across all genotypes in 136 patients. The safety profile was favorable with only 4.4% mild ARIA-H, even among high-risk APOE4 homozygotes, and there were no treatment-related discontinuations. Biomarker data indicated early target engagement, with 68.5% of patients showing a decline in plasma pTau217 and 62.5% showing a decline in CSF MTBR-tau243. These blinded trends align with the trial's 3:1 active-to-placebo ratio but are not yet determinative of efficacy.
Key figures
- Drug Name
- PMN310
- Phase Of Trial
- Phase 1b
- Aria h rate
- 4.4%
- Aria e cases
- 0
- Total enrolled
- 144
- Interim patients
- 136
- Apoe4 carrier rate
- 61%
- Dose cohorts mg kg
- [5,10,20]
- Apoe4 homozygote rate
- 11%
- Plasma ptau217 decline
- 68.5%
- Active to placebo ratio
- 3:1
- Csf mtbr tau243 decline
- 62.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.